It has also been investigated how HIF-1 affects TNBC through chemotherapy, immunotherapy, anti-angiogenic therapy, adjuvant therapy, PDT, adoptive cell therapy, antibody drug conjugates, cancer vaccines and also in combination therapies. This evidence concerns the gene HIF1A and cancer.